Daniel S. Levine

Daniel S. Levine is editor of Rare Daily. You can contact him by sending email to editor@globalgenes.org

Why Rare Disease Drug Developers Need Regular Interaction with the FDA
Despite accelerated pathways for the development and approval of rare disease therapies, significant challenges remain for companies wishing… Continue Reading
Abeona Therapeutics Appoints New CMO
Rare Daily Staff Abeona Therapeutics said it appointed João Siffert, an industry veteran with medical and academic experience, as head of… Continue Reading
AveXis Submits SMA Gene Therapy for Regulatory Approval in U.S., Europe, and Japan
Rare Daily Staff AveXis, in a letter addressed to the spinal muscular atrophy community, said it submitted regulatory applications in the… Continue Reading
Rare Leader: Dawn Ireland, President, CDH International
The Basics Name: Dawn Ireland Title: President Organization: CDH International Disease focus: Congenital diaphragmatic hernia is a birth… Continue Reading
SMA Drug Developers Share $3 Million Breakthrough Prize
Rare Daily Staff Ionis Pharmaceuticals pharmacologist Frank Bennett and Cold Spring Harbor Laboratory Biochemist Adrian Krainer will share a… Continue Reading
FDA Issues Draft Guidance on Pre-IND Meetings for Rare Disease Drug Development
Rare Daily Staff The U.S. Food and Drug Administration issued a draft guidance addressing the role of meetings with the agency prior to… Continue Reading
CDC Expresses Concern about Emerging Cases of Rare, Paralyzing Disease
Rare Daily Staff The U.S. Centers for Disease Control and Prevention said since August of 2014, it has seen an increase in the number of… Continue Reading

Follow us on Twitter